PDHX

Across TCGA pan-cancer cohorts, PDHX mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PDHX’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PDHX mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PDHX is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where PDHX tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDHX mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−1.092	<.001	12	view →
HNSC	All	II,III,IV	−0.968	<.001	11	view →
LUAD	Female	All	+0.316	<.001	8	view →
PDAC	Female	All	−0.611	<.001	7	view →
COAD	All	All	−0.097	.003	5	view →
LSCC	All	All	+0.117	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PDHX–CCRCC

Open the CCRCC breakdown →